Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review

Zachary Green; Robert Mark Beattie; James J Ashton

doi:10.21037/tp-23-210

Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review

Transl Pediatr. 2023 Oct 30;12(10):1853-1874. doi: 10.21037/tp-23-210. Epub 2023 Oct 27.

Authors

Zachary Green^{1

2}, Robert Mark Beattie¹, James J Ashton^{1

3}

Affiliations

¹ Department of Paediatric Gastroenterology, Southampton Children's Hospital, Southampton, UK.
² Department of Paediatric Gastroenterology, Noah's Ark Children's Hospital for Wales, Cardiff, UK.
³ Department of Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK.

Abstract

Background and objective: The landscape of paediatric inflammatory bowel disease (pIBD) continues to evolve in an era of increasing incidence. There have been rapid developments in understanding, as we begin to perceive IBD as a spectrum of conditions, alongside advancements in monitoring and treatment. The objective of this article was to provide an overview of recent advances and challenges in the management of pIBD, with a focus on sustainable healthcare, personalised therapy, genomics, new drugs and avenues for future optimisation.

Methods: We present a narrative review that synthesises and summarises recent research (2017-2022) related to pIBD. We undertook a structured search of the literature (PubMed and Medline) and additional articles were identified through manual searches of reference lists. Evidence tables were compiled for disease outcomes.

Key content and findings: In this review we outline current practice, integrating clinical guidelines and contemporary research. We discuss initial investigations (including suggested threshold for paediatric faecal calprotectin), specialist investigations for disease monitoring [with reference to video capsule endoscopy (VCE) and therapeutic drug levels] and outline new and established treatment options. Biomarkers and genomic testing are examined as important tools for individualising care and identifying potential therapeutic targets, including for top-down therapy. Despite these advances, significant challenges remain, including the need for further research to understand the mechanisms of disease and the translation of these advances into real-world improvements in practice.

Conclusions: Recent advances in understanding of the pathogenesis of pIBD, alongside genomic and pharmacological developments have added more tools to the armamentarium for the treatment of these conditions and highlighted ongoing areas of research need.

Keywords: Crohn’s disease; Paediatric; inflammatory bowel disease (IBD); ulcerative colitis.

Publication types

Review